# AstraZeneca signs $2 billion agreement with Quell to develop cell therapies
Published: 2023-06-09
Category: News
Category URL: https://technologydispatch.com/category/news/
Meta Title: AstraZeneca signs $2 billion deal with Quell for cell
Meta Description: AstraZeneca partners with Quell Therapeutics in a $2 billion deal to develop cell therapies for autoimmune diseases like type 1 diabetes and inflammatory bowel
URL: https://technologydispatch.com/astrazeneca-signs-2-billion-agreement-with-quell-to-develop-cell-therapies/

![undefined](https://prod.superblogcdn.com/site_cuid_cm5qslpr5001pwirgs7x8860d/images/2023-06-09t080503z2lynxmpej58078rtroptp4astrazeneca-quell-therapeutics-autoimmune-1737018654542-compressed.jpg)

(Reuters) – AstraZeneca said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.

The agreement includes developing, manufacturing and commercialising cell therapies that have the potential to be curative in type 1 diabetes and inflammatory bowel disease indications, the drugmaker said in a statement.

UK-based Quell will receive $85 million upfront from AstraZeneca, and is also eligible to receive over $2 billion for further development and commercialisation milestones, the company added.

(Reporting by Radhika Anilkumar in Bengaluru; Editing by Rashmi Aich)


---
This blog is powered by Superblog. Visit https://superblog.ai to know more.
---